HTGMQ — HTG Molecular Diagnostics Share Price
Last trade - 00:00- $0.00m
- $0.33m
- $6.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -454.8% | ||
| Return on Equity | -343.21% | ||
| Operating Margin | -315.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.5 | 19.2 | 8.55 | 8.91 | 6.37 | 6.4 | 15 | -15.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company's Gene Expression Panels include HTG Research Use Only (RUO) Panels and HTG EdgeSeq Research Use Only (RUO) Panels, such as the HTG Transcriptome Panel, HTG EdgeSeq miRNA Whole Transcriptome Assay, HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq Precision Immuno-Oncology Panel, HTG EdgeSeq Immune Response Panel, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG EdgeSeq Mouse mRNA Tumor Response Panel, and HTG EdgeSeq DLBCL Cell of Origin Assay. The HTG EdgeSeq system provides gene expression profiling for researchers, laboratory staff, and biomarker leads in discovery, translational medicine, and oncology applications. VERI/O Laboratory Services is a molecular lab providing gene expression profiling results.
Directors
- Ann Hanham NEC (68)
- John Lubniewski PRE (57)
- Shaun Mcmeans CFO (59)
- Stephen Barat SVP
- Byron Lawson SVP (46)
- Christopher Kiritsy DRC (56)
- Harry George IND (73)
- Michelle Griffin IND (55)
- Donnie Hardison IND (70)
- James Lafrance IND (62)
- Lee McCracken IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- December 14th, 2000
- Public Since
- May 6th, 2015
- No. of Shareholders
- 57
- No. of Employees
- 53
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 2,214,233
- Address
- 3430 E Global Loop, TUCSON, 85706-5009
- Web
- https://www.htgmolecular.com/
- Phone
- Auditors
- BDO USA, LLP
Upcoming Events for HTGMQ
Similar to HTGMQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 21:09 UTC, shares in HTG Molecular Diagnostics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in HTG Molecular Diagnostics last closed at $0.00 and the price had moved by -93.33% over the past 365 days. In terms of relative price strength the HTG Molecular Diagnostics share price has underperformed the S&P500 Index by -93.77% over the past year.
The overall consensus recommendation for HTG Molecular Diagnostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHTG Molecular Diagnostics does not currently pay a dividend.
HTG Molecular Diagnostics does not currently pay a dividend.
HTG Molecular Diagnostics does not currently pay a dividend.
To buy shares in HTG Molecular Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in HTG Molecular Diagnostics had a market capitalisation of $0.00m.
Here are the trading details for HTG Molecular Diagnostics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HTGMQ
Based on an overall assessment of its quality, value and momentum HTG Molecular Diagnostics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in HTG Molecular Diagnostics is $6.00. That is 5999900% above the last closing price of $0.00.
Analysts covering HTG Molecular Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -$4.63 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HTG Molecular Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -74.12%.
As of the last closing price of $0.00, shares in HTG Molecular Diagnostics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HTG Molecular Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HTG Molecular Diagnostics' management team is headed by:
- Ann Hanham - NEC
- John Lubniewski - PRE
- Shaun Mcmeans - CFO
- Stephen Barat - SVP
- Byron Lawson - SVP
- Christopher Kiritsy - DRC
- Harry George - IND
- Michelle Griffin - IND
- Donnie Hardison - IND
- James Lafrance - IND
- Lee McCracken - IND